NOW APPROVED
hero-secondary
A ship breaks through icebergs that reflect the many challenges in treating mPDAC and targeting RAS.
For APPs and RNs
Resources and detailed information for APPs and RNs, including dosing, dose modifications, and prophylaxis, to help you care for patients who are prescribed RASONQUE.
spacing-xl
styled-text
Resources for your team and your patients
margin-bottom-lg
mobile-margin-bottom-20
text-color-corazon
fit
true
m
stretch
start
false
callout-banner
without-image
Dosing & Adverse Reaction Management Guide
Find detailed prophylaxis recommendations, dose management, and patient education resources for the most common ARs of RASONQUE.
Download
blue-tint
solid-denim
callout-banner
without-image
Dermatologic Reactions Management Guide
Information about dermatologic reactions associated with RASONQUE and their management
Download
blue-tint
solid-denim
spacing-sm
mobile-spacing-sm
spacing-sm
mobile-spacing-sm
spacing-md
spacing-xl
styled-text
2 tablets taken orally, once daily1
margin-bottom-sm
mobile-margin-bottom-20
text-color-corazon
Tablets not actual size.
- Recommended dosage: 300 mg (two 150-mg tablets)
300 mg (two 150 mg tablets).
spacing-xl
mobile-spacing-sm
default
none
Pill with water.
RASONQUE can be taken with or without food1
- Tablets should be swallowed whole. They should not be chewed, crushed, or split
Clock.
RASONQUE should be taken at the same time each day1
- If a dose is missed for more than 4 hours, skip the missed dose, and take the next dose at the next regularly scheduled time
- If vomiting occurs after taking the dose, do not take an additional dose. Resume dosing at the next regularly scheduled time
- RASONQUE is available as 150-mg and 100-mg tablets
spacing-md
spacing-xl
styled-text
Summary of prophylactic measures and patient education
margin-bottom-sm
text-color-corazon
styled-text
Discussing prophylaxis and ARs with patients and caregivers is an important first step in their treatment with RASONQUE
margin-bottom-sm
text-color-denim-blue
styled-text
When initiating RASONQUE and throughout treatment, prophylactic and concomitant medications (eg, topical corticosteroids, emollient creams, sunscreen, oral antibiotics) are recommended to reduce the risk of dermatologic reactions1*
margin-bottom-md
text-color-90-black
graphic
Consider additional prophylaxis and patient education asterisk: rash1-4, nausea/comiting3, stomatitis/mucositis2,3, diarrhea2,3.
spacing-md
spacing-xl
mobile-spacing-xxs
styled-text
*Prophylaxis for dermatologic reactions was recommended but not required in RASolute 302.3
margin-top-xs
mobile-margin-top-10
text-color-90-black
spacing-xl
spacing-xl
styled-text
Dermatologic reactions: Profile and incidence
margin-bottom-sm
text-color-corazon
styled-text
Monitoring and onset in RASolute 302*
margin-bottom-sm
text-color-denim-blue
styled-text
- Safety assessments for patients receiving RASONQUE were performed every 2 weeks and as clinically indicated3
margin-bottom-sm
text-color-90-black
styled-text
Profile
margin-bottom-sm
text-color-denim-blue
styled-text
-
Rash is a common, expected side effect that was seen in patients treated with RASONQUE from the RASolute 302 trial1
- The majority of cases were Grade 1 or Grade 2 in severity
-
It is typically an acneiform rash2
-
In clinical trials of patients with pancreatic adenocarinoma1†:
- Median time to first onset of dermatologic toxicity was 13 days (range: 1 to 106 days)
- Median time to improvement of dermatologic toxicity from Grade 3 to Grade 1 or resolution was 16 days (range: 8 to 218 days)
margin-bottom-lg
text-color-90-black
styled-text
Rash of any grade occurred in 87% of patients in RASolute 3021‡
margin-bottom-sm
text-color-black
graphic
Dermatologic reactions occurring in greater than or equal to 10% of patients who received RASONQUE in RASolute 3021: rash double dagger, dry skin, and pruritus.
spacing-md
styled-text
Dose interruptions, modifications, and permanent discontinuations in patients who received RASONQUE in RASolute 3021
margin-bottom-sm
text-color-denim-blue
styled-text
- Dose interruptions in ≥5% of patients: 27% due to rash1
- Dose reductions in ≥5% of patients: 18% due to rash1
- Permanent discontinuations in 2.9% of patients: 0.8% due to rash1
margin-bottom-md
mobile-margin-bottom-10
text-color-90-black
styled-text
*Prophylaxis for dermatologic reaactions was recommended but not required in RASolute 302.3
†The pooled safety population of RASONQUE reflects exposure to RASONQUE 300 mg once daily in 241 patients with pancreatic adenocarcinoma enrolled in RASolute 302 and 184 patients with pancreatic adenocarcinoma enrolled in the open‑label trial RMC-6236-001.1
‡Graded per NCI CTCAE Version 5.0.1
§Includes multiple related terms.1
text-color-90-black
spacing-xl
mobile-spacing-lg
styled-text
Initiate prophylactic measures prior to the first dose to reduce the risk of moderate to severe dermatologic reactions1
margin-top-md
margin-bottom-sm
text-color-corazon
styled-text
Prophylactic and proactive dermatologic reaction management is important to support patients1
margin-bottom-sm
text-color-denim-blue
styled-text
Monitor for signs and symptoms and treat as medically appropriate.
text-color-90-black
spacing-lg
mobile-spacing-md
grid
plus
Topical corticosteroids
Topical corticosteroids1-3
- Face: eg, hydrocortisone 2.5% BID
- Chest: eg, triamcinolone 0.1% BID
Emollient cream
Emollient cream1-3
- Fragrance-free, emollient moisturizing cream
Sunscreen
Sunscreen1-4
- SPF ≥30 applied ≥30 minutes before sun exposure. Advise patients to reapply every 2 hours
Oral antibiotics
Oral antibiotics1-3
Consider:
- Eg, doxycycline 100 mg BID or minocycline 50 mg BID
- Initiate prior to first dose of RASONQUE and as clinically indicated throughout treatment
spacing-lg
mobile-spacing-md
styled-text
Advise patients to limit sun exposure and wear protective clothing, including a hat, if they are in the sun5
margin-bottom-md
mobile-margin-bottom-10
text-color-black
styled-text
*Prophylaxis for dermatologic reactions was recommended but not required in RASolute 302.3
margin-bottom-xxl
mobile-margin-bottom-30
text-color-black
styled-text
Tips to help patients and caregivers with day-to-day management of dermatologic reactions
margin-top-xl
margin-bottom-md
mobile-margin-top-30
mobile-margin-bottom-30
text-color-black
row
vertical
Shower head.
Skin hygiene6
- Keep skin clean with mild soap
- Avoid hot water
- Gently pat skin dry
- Consider an OTC antiseptic spray (eg, hypochlorous acid; AM/PM)
Sweatshirt.
Clothing and toiletries6
- Wear loose, soft, comfortable clothing
- Avoid strong perfumes or irritating chemicals
Body with spots inspected by magnifying glass.
Self-check6
- Perform full-body exams frequently to monitor for new or worsening reactions
Bottle next to sun.
Sun protection1,2,5
- Avoid direct sun exposure
- Use sunscreen that is SPF ≥30, applied ≥30 minutes before sun exposure
- Wear protective clothing, hats, and gloves
styled-text
Additional resources are available to help manage dermatologic reactions
margin-top-xl
margin-bottom-sm
text-color-corazon
styled-text
- Dermatologic Reactions Management Guide
- Dosing & Adverse Reaction Management Guide
margin-bottom-md
mobile-margin-bottom-none
text-color-black
spacing-xl
spacing-xl
styled-text
Stomatitis/mucositis
margin-bottom-sm
text-color-corazon
styled-text
Profile
margin-bottom-xs
text-color-denim-blue
styled-text
Stomatitis/mucositis is inflammation or irritation of the mucous membranes in the mouth, characterized by redness, ulcers, and white patches. Stomatitis includes aphthous ulcer, mucosal inflammation, mucosal ulceration, and stomatitis.7,8
margin-bottom-xs
text-color-black
styled-text
-
In clinical trials of patients with pancreatic adenocarinoma1*:
- Median time to first onset of stomatitis was 22 days (range: 1 to 343 days)
- Median time to improvement of stomatitis from Grade ≥3 to Grade 1 or resolution was 12 days (range: 1 to 127 days)1
margin-bottom-md
text-color-black
styled-text
Stomatitis of any grade occurred in 56% of patients in RASolute 3021†
margin-bottom-sm
text-color-90-black
graphic
Grades 1-2 stomatitis/mucositis occurred in 43% of patients, and greater than or equal to grade 3 stomatitis/mucositis occurred in 13% of patients.
spacing-lg
mobile-spacing-md
styled-text
Dose modifications and permanent discontinuations in patients who received RASONQUE:
text-color-denim-blue
styled-text
- Dose interruptions in ≥5% of patients: 20% due to stomatitis1
- Dose reductions in ≥5% of patients: 8% due to stomatitis1
margin-bottom-xl
text-color-90-black
styled-text
Patient education
margin-top-lg
margin-bottom-sm
mobile-margin-top-40
text-color-denim-blue
styled-text
Educate patients on managing stomatitis/mucositis‡
margin-bottom-sm
mobile-margin-bottom-30
text-color-90-black
row
vertical
Tooth surrounded by sun and moon.
Oral hygiene2,3,9
- Brush and floss at least twice a day
- Use a saline (salt water) rinse
- Avoid mouthwashes with alcohol
Consider§:
- Keeping lips moisturized with a lip balm
- Using a soft-bristled toothbrush
Water bottle and bananas.
Diet2,3,9,10
- Avoid rough and sharp foods
Consider§:
- Avoiding foods that are hot in temperature
- Avoiding acidic fruits and juices
- Eating chilled foods and drinking chilled fluids
- Eating soft foods that are not too dry and are easy to swallow
Circle-backslash symbol.
Lifestyle2,3
- Avoid alcohol and tobacco
styled-text
*The pooled safety population of RASONQUE reflects exposure to RASONQUE 300 mg once daily in 241 patients with pancreatic adenocarcinoma enrolled in RASolute 302 and 184 patients with pancreatic adenocarcinoma enrolled in the open‑label trial RMC-6236-001.1
†Graded per NCI CTCAE Version 5.0.1
‡Prophylaxis was recommended but not required in RASolute 302.3
§These recommendations are adapted from the American Cancer Society.
margin-top-md
mobile-margin-top-30
text-color-90-black
spacing-xl
spacing-xl
styled-text
Diarrhea
margin-bottom-sm
text-color-corazon
styled-text
Profile
margin-bottom-xs
text-color-denim-blue
styled-text
-
In clinical trials of patients with pancreatic adenocarinoma1*:
- Median time to first onset of diarrhea was 3 days (range: 1 to 260 days)
- Median time to improvement of diarrhea from Grade ≥3 to Grade 1 or resolution was 3 days (range: 1 to 21 days)1
margin-bottom-sm
text-color-90-black
styled-text
Diarrhea of any grade occurred in 67% of patients receiving RASONQUE in RASolute 3021†
margin-bottom-sm
text-color-black
graphic
Grades 1-2 diarrhea occurred in 61% of patients, and greater than or equal to grade 3 diarrhea occurred in 6% of patients.
styled-text
Serious AR, dose interruption, and dose reduction rates in patients who received RASONQUE1
margin-top-xl
mobile-margin-top-30
text-color-denim-blue
styled-text
- Serious ARs in ≥2% of patients: 3.7% due to diarrhea1
- Dose interruptions in ≥5% of patients: 8% due to diarrhea1
- Dose reductions in ≥5% of patients: 5% due to diarrhea1
margin-bottom-xl
text-color-90-black
styled-text
Patient education‡
margin-top-lg
margin-bottom-sm
mobile-margin-top-40
mobile-margin-bottom-40
text-color-denim-blue
row
vertical
Clipboard.
Management and reporting2,3,11,12
- Educate patients on the proper use of antidiarrheal medication
Consider§:
- Encouraging patients to keep track of how often diarrhea occurs
- Pancreatic enzyme replacement therapy, as clinically indicated
Water bottle and banana.
Modified diet2,3,11
- Consider the BRAT diet if needed (banana, rice, applesauce, toast)
Consider encouraging patients to§:
- Drink plenty of water and fluids to replace electrolytes
- Eat small meals throughout the day
- Eat foods that are high in sodium and potassium
Circle-backslash symbol.
Consider avoiding11
- High-fiber foods
- Food and drinks that can make diarrhea worse, like alcohol, dairy, spicy foods, and caffeine
styled-text
*The pooled safety population of RASONQUE reflects exposure to RASONQUE 300 mg once daily in 241 patients with pancreatic adenocarcinoma enrolled in RASolute 302 and 184 patients with pancreatic adenocarcinoma enrolled in the open‑label trial RMC-6236-001.1
†Graded per NCI CTCAE Version 5.0.1
‡Prophylaxis was recommended but not required in RASolute 302.3
§These recommendations are adapted from the National Cancer Institute.
margin-top-lg
text-color-90-black
spacing-xl
spacing-xl
spacing-sm
styled-text
APP=advanced practice provider; AR=adverse reaction; BID=twice a day; OTC=over the counter; RN=registered nurse; SPF=sun protection factor.
margin-top-none
margin-bottom-none
mobile-margin-top-none
mobile-margin-bottom-none
text-color-90-black
spacing-lg
mobile-spacing-lg
styled-text
References: 1. RASONQUE. Prescribing information. Revolution Medicines, Inc.; 2026. 2. Data on file. Revolution Medicines, Inc.; 2026. 3. Protocol for: O’Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMoa2605555 4. Kaminsky A, Suhl S, Sacknovitz Y, Schwartz GK, Deverapalli S, Geskin LJ. Skin health in oncology: evidence-based skin care for cancer patients. Oncologist. 2026;31(7):oyag194. doi:10.1093/oncolo/oyag194 5. RASONQUE. Medication Guide. Revolution Medicines, Inc.; 2026. 6. Rashes and skin changes. Atlanta: American Cancer Society, 2026. Accessed July 5, 2026. https://www.cancer.org/cancer/managing-cancer/side-effects/hair-skin-nails/rashes-skin-changes.html 7. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008;52(1):61-77. doi:10.1016/j.cden.2007.10.002 8. O’Reilly EM, Wainberg ZA, Hendifar AE, et al; RASolute 302 Trial Investigators. Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med. Published online May 31, 2026. doi:10.1056/NEJMoa2605555 9. Mouth soreness and pain. Atlanta: American Cancer Society, 2026. Accessed April 14, 2026. https://www.cancer.org/cancer/managing-cancer/side-effects/eating-problems/mouth-sores.html 10. Oral complications of cancer therapies (PDQ®)–health professional version. National Cancer Institute. Accessed June 14, 2026. https://www.cancer.gov/about-cancer/treatment/side-effects/mouth-throat/oral-complications-hp-pdq 11. Diarrhea and cancer treatment. National Cancer Institute. Accessed June 14, 2026. https://www.cancer.gov/about-cancer/treatment/side-effects/diarrhea 12. Brennan GT, Saif MW. Pancreatic enzyme replacement therapy: a concise review. JOP. 2019;20(5):126-129.
text-color-black
spacing-xl
mobile-spacing-xl